0000950170-24-025933.txt : 20240305
0000950170-24-025933.hdr.sgml : 20240305
20240305161517
ACCESSION NUMBER: 0000950170-24-025933
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240304
FILED AS OF DATE: 20240305
DATE AS OF CHANGE: 20240305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sapir Alex
CENTRAL INDEX KEY: 0001709415
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38978
FILM NUMBER: 24720569
MAIL ADDRESS:
STREET 1: C/O DOVA PHARMACEUTICALS, INC.
STREET 2: 240 LEIGH FARM ROAD, SUITE 245
CITY: DURHAM
STATE: NC
ZIP: 27707
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fulcrum Therapeutics, Inc.
CENTRAL INDEX KEY: 0001680581
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 474839948
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-651-8851
MAIL ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
ownership.xml
4
X0508
4
2024-03-04
0001680581
Fulcrum Therapeutics, Inc.
FULC
0001709415
Sapir Alex
C/O FULCRUM THERAPEUTICS, INC.
26 LANDSDOWNE STREET
CAMBRIDGE
MA
02139
true
true
false
false
See Remarks
false
Common Stock
2024-03-04
4
P
false
43360
11.3475
A
43360
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.96 to $11.50, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
President & Chief Executive Officer
/s/ Greg Tourangeau as attorney-in-fact for Alex Sapir
2024-03-05